Group Gp Lp Column III Buys 1,034,482 Shares of Surrozen, Inc. (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average price of $11.60 per share, for a total transaction of $11,999,991.20. Following the acquisition, the insider now directly owns 795,411 shares of the company’s stock, valued at approximately $9,226,767.60. The trade was a -432.71 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Surrozen Stock Performance

SRZN stock opened at $11.01 on Friday. The business has a fifty day simple moving average of $11.37 and a 200-day simple moving average of $10.96. Surrozen, Inc. has a 52 week low of $6.00 and a 52 week high of $18.17.

Institutional Investors Weigh In On Surrozen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in shares of Surrozen by 26.1% in the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock valued at $321,000 after purchasing an additional 4,630 shares in the last quarter. Trustees of Columbia University in the City of New York acquired a new position in Surrozen during the fourth quarter valued at approximately $688,000. Adage Capital Partners GP L.L.C. acquired a new position in Surrozen during the fourth quarter valued at approximately $928,000. Regents of The University of California purchased a new stake in Surrozen during the fourth quarter worth approximately $1,912,000. Finally, Stonepine Capital Management LLC increased its position in shares of Surrozen by 24.7% in the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock worth $1,969,000 after acquiring an additional 27,200 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SRZN has been the topic of a number of research analyst reports. HC Wainwright began coverage on Surrozen in a research note on Thursday, January 30th. They issued a “buy” rating and a $32.00 price target on the stock. Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price on the stock in a research report on Friday, January 3rd.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.